UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 122

Sortiert nach

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

Cephalalgia, 2016-08, Vol.36 (9), p.887-898

2016

Link zum Volltext

Verfügbarkeit prüfen

Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study

Headache, 2008-09, Vol.48 (8), p.1157-1168

2008

Link zum Volltext

Verfügbarkeit prüfen

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Headache, 2020-01, Vol.60 (1), p.141-152

2020

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study

Journal of headache and pain, 2018-05, Vol.19 (1), p.38-9, Article 38

2018

Link zum Volltext

Verfügbarkeit prüfen

Medication overuse headache

Nature reviews. Disease primers, 2023-02, Vol.9 (1), p.5-5, Article 5

2023

Link zum Volltext

Verfügbarkeit prüfen

Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial

Journal of headache and pain, 2024-05, Vol.25 (1), p.83-83

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

Journal of headache and pain, 2023-08, Vol.24 (1), p.102-102, Article 102

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Headache, 2007-02, Vol.47 (2), p.170-180

2007

Link zum Volltext

Verfügbarkeit prüfen

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

Advances in therapy, 2021-10, Vol.38 (10), p.5209-5220

2021

Link zum Volltext

Verfügbarkeit prüfen

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

Journal of headache and pain, 2022-04, Vol.23 (1), p.50-50, Article 50

2022

Link zum Volltext

Verfügbarkeit prüfen

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

Journal of headache and pain, 2022-02, Vol.23 (1), p.22-22, Article 22

2022

Link zum Volltext

Verfügbarkeit prüfen

Preventive Treatment of Migraine

Continuum (Minneapolis, Minn.), 2024-04, Vol.30 (2), p.364

Lipton, Richard B

2024

Link zum Volltext

Verfügbarkeit prüfen

Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention

Headache, 2015-03, Vol.55 (S2), p.103-122

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Journal of headache and pain, 2019-01, Vol.20 (1), p.10-10, Article 10

2019

Link zum Volltext

Verfügbarkeit prüfen

Migraine day frequency in migraine prevention: longitudinal modelling approaches

BMC medical research methodology, 2019-01, Vol.19 (1), p.20-20, Article 20

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Tolerability of Calcitonin Gene–Related Peptide–Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine

Pain medicine (Malden, Mass.), 2021-08, Vol.22 (8), p.1857-1863

2021

Link zum Volltext

Verfügbarkeit prüfen

The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis

Value in health, 2009, Vol.12 (1), p.55-64

2009

Link zum Volltext

Verfügbarkeit prüfen

Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society

Headache, 2008-06, Vol.48 (6), p.778-782

2008

Link zum Volltext

Verfügbarkeit prüfen

Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine

Headache, 2004-05, Vol.44 (5), p.414-425

2004

Link zum Volltext

Verfügbarkeit prüfen

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults

Headache, 2024-03, Vol.64 (3), p.266-275

2024

Link zum Volltext

Verfügbarkeit prüfen

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

Headache, 2022-10, Vol.62 (9), p.1153-1163

2022

Link zum Volltext

Verfügbarkeit prüfen

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Cephalalgia, 2022-01, Vol.42 (1), p.3-11

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Headache, 2021-04, Vol.61 (4), p.642-652

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex

Cephalalgia, 2024-03, Vol.44 (3), p.3331024241238153-3331024241238153

2024

Link zum Volltext

Verfügbarkeit prüfen

A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine

Cephalalgia, 2024-04, Vol.44 (4), p.3331024241232944-3331024241232944

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 122

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

ThemaMigraine Disorders - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(116)

Publikationsform

Artikel
(122)

Sprache

Englisch
(122)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study

Medication overuse headache

Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

Preventive Treatment of Migraine

Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Migraine day frequency in migraine prevention: longitudinal modelling approaches

Efficacy and Tolerability of Calcitonin Gene–Related Peptide–Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine

The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis

Defining Refractory Migraine and Refractory Chronic Migraine: Proposed Criteria From the Refractory Headache Special Interest Section of the American Headache Society

Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study

Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex

A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine

Aktive Filter

Suchergebnisse filtern